News related to
data

Yunfeng Financial Group, a Hong Kong‑listed firm with ties to Alibaba’s Jack Ma, has acquired 10,000 ETH—valued at approximately $44 million—using its own cash reserves. The firm intends to list Ether as an investment on its balance sheet as part of a strategic shift towards blockchain-enabled finance.

Yunfeng’s move aligns with its broader blueprint unveiled in July, which sets Web3 technologies, real-world asset tokenisation and artificial intelligence at the heart of its expansion strategy. The company emphasises that including Ether among its strategic reserve assets supports tokenisation efforts and integrates its financial operations with Web3 infrastructure. The firm also plans to explore Ethereum’s uses in insurance services and decentralised finance applications, signalling ambitions beyond treasury diversification.

This step places Yunfeng alongside a growing list of publicly traded firms embracing Ether as a reserve asset. Notable peers include SharpLink Gaming, BitMine Immersion Technologies and Ether Machine, which collectively reflect a broader institutional enthusiasm for Ethereum amid increasing corporate treasury adoption. The trend echoes earlier Fortune 500 strategies for Bitcoin, with Ethereum emerging as a comparable asset in this evolving corporate playbook.

Ether’s market resilience underpins Yunfeng’s strategy. Despite subdued crypto market conditions, ETH continues to trade above the psychologically significant $4,000 threshold, noted by analysts as a key marker of investor confidence. Technical analysis by market watchers, including the chartist CryptoGoos, suggests ETH is maintaining an upward breakout trend from a falling wedge formation, with potential upside targets stretching to $6,000—driven by heightened institutional inflows.

Yunfeng’s approach signals a calculated embrace of digital assets that transcends short‑term speculation. By positioning Ethereum at the foundational level of its Web3 and AI strategy, the company is asserting the utility of the token within financial services, as well as its role as a long‑term reserve option. Ether holdings will offer an alternative to traditional fiat reliance while granting greater operational flexibility across emerging business lines.

Shiba Inu has bounced off a decisive demand zone, reclaiming support near $0.000012 and positioning itself for potential upward movement toward $0.000015, as technical charts and market dynamics align in favour of bulls.

The meme token recently rallied from a support cluster between $0.0000115 and $0.000012, forming a reassuring double‑bottom pattern that underscores emerging buying interest. Observers note that if this momentum holds, SHIB could head toward its key short‑term resistance around $0.000015. Analysts emphasise that sustaining pressure above this demand zone is critical to maintaining bullish prospects.

A chart pattern also suggests that SHIB is attempting to break above a descending channel, lying just below its 50‑day moving average. Crossing that threshold could trigger a sharper rally, with targets stretching to $0.000014, $0.0000175, and even beyond, provided higher timeframe breakouts materialise.

Adding fuel to the rally, token burns have surged significantly—over 48,000% in one documented instance—with tens of millions of SHIB permanently removed from circulation. This deflationary action tightens supply and, combined with heightened derivatives activity, bolsters bullish sentiment.

Yet, technical caution is advised. SHIB is currently compressed within a symmetrical triangle near $0.0000123, and the direction of the breakout—either above $0.000013 or below $0.00001—will likely determine whether bullish or bearish trajectories dominate. A clean advance above the upper trendline and rising volume would open the door toward $0.000015 and the 200‑day moving average; conversely, a breakdown could expose support near $0.0000095.

Beyond price mechanics, structural developments around the Shiba Inu ecosystem—such as Layer‑3 platform expansion, burn infrastructure, and community governance initiatives—offer a long‑term narrative that could support sustained demand, though analysts caution that burns and buzz alone may not suffice without wider utility adoption.

In essence, Shiba Inu now stands at an inflection point. A firm hold above the demand zone has reignited interest, and a break above the 50-day MA or the triangle’s upper boundary could spark a more pronounced rally. Conversely, failure to defend current levels risks deeper retracement. Technology upgrades, ecosystem growth, and on-chain developments remain key components shaping its trajectory.

Pharmaceutical developers are making headway with artificial intelligence tools to model drug absorption, distribution, and toxicity in human-relevant systems. This shift supports the U. S. Food and Drug Administration’s initiative to make animal testing an exception rather than a rule, particularly in pre‑clinical safety assessments for monoclonal antibody therapies and other drugs.

Regulatory authorities expect New Approach Methodologies—including AI-driven computational models, human-cell‑based systems like organs‑on‑chips, and organoids—to halve both development time and costs within the next three to five years. Recursion Pharmaceuticals recently advanced a cancer drug candidate to clinical trials in just 18 months, markedly faster than the 42‑month industry average.

The FDA’s April roadmap encourages drug developers to submit safety data from NAMs in Investigational New Drug applications. Firms providing robust NAM evidence may receive streamlined review processes—a concrete incentive to adopt these modern methods. A pilot programme allows select monoclonal antibody developers to use primarily non‑animal testing strategies, with results shaping future guidance.

Industry leaders at Charles River, Certara, Schrodinger, Recursion and InSphero are investing heavily in these emerging tools. Charles River’s NAM portfolio now generates roughly US $200 million annually. Certara’s president, Patrick Smith, stated the company is reaching a point where animal testing may no longer be necessary. Schrodinger utilises physics‑based simulations with AI to predict potential toxicity, while InSphero tests safety and efficacy using 3D liver microtissue models.

This transition builds on milestones such as the FDA Modernization Act 2.0, which removed the default requirement for animal data in drug development and formally recognised in vitro, in silico, and organ‑based methods as valid non‑clinical evidence. The Act is part of a broader regulatory overhaul that began with the ISTAND programme—for qualifying organ-on-chip tools—and continued with acceptance of the first liver‑chip into that pathway in 2024. Additional momentum comes from shifts in funding and policy: the NIH now prioritises human‑based models and no longer supports animal‑only proposals; the U. S. Navy has ended cat and dog experiments; and a federal push is underway to align academic and industry research with NAMs adoption.

Beyond regulation, academic research underscores the promise of computational approaches. A June 2025 study highlights AI and deep learning as enablers of predictive frameworks for vaccine and immunotherapeutic design—pointing toward a future where animal testing is replaced by computational models that refine vaccine targets and immune response predictions.

In parallel, the FDA is advancing its broader modernisation agenda through pilot programmes aimed at accelerating drug review timelines. Commissioner Marty Makary has proposed a split‑submission process that allows early review of key data during clinical trials. Coupled with AI tools such as Elsa—used daily within the FDA to expedite data review—this approach is projected to compress approval times from 10–12 months to as little as one to two months in eligible cases.

Ethically, these developments carry weight. Animal testing has repeatedly fallen short in predicting human outcomes—about 90 per cent of drugs deemed safe in animals fail in humans. New methods rooted in human biology promise not just faster, cost‑efficient drug pipelines, but also greater relevance and reliability in safety assessments, while reducing ethical concerns.

Though a complete end to animal testing is not expected immediately, experts anticipate a hybrid landscape in the short term, with animal studies still used where necessary but significantly reduced in favour of AI and human‑based alternatives.

A sharp rebound in the Taiwan dollar has intensified financial pressure on exporters, undermining earnings and dampening competitiveness in overseas markets. The appreciation, driven by a blend of strong trade inflows, hedging activities, and speculative pressures, has prompted swift policy attention and heightened concern among industry observers.

Taiwan’s currency surged to its highest level since early 2022—landing near NT$29 per U. S. dollar—amid a weakening U. S. dollar and heightened equity inflows. The rally, measuring around 12 per cent so far this year, has inflicted renewed strain on leading exporters, including Taiwan Semiconductor Manufacturing Company and Foxconn, which report substantial margin erosion when the Taiwan dollar strengthens.

Exporters are finding that every one‑unit appreciation of the currency can slash revenue by roughly 3 per cent and chip away at gross margins—Foxconn estimates its margins dip by 0.1 percentage point per NT$1 gain. Smaller, traditional manufacturers—especially machinery producers—are even more exposed, with limited hedging capacity and tighter operating margins.

Life insurers are not spared. Many hold a sizable portion of assets in U. S. dollars—Fubon Financial, for example, has about 70 per cent of its portfolio in foreign holdings—and face amplified foreign‑exchange losses as the local currency climbs.

Regulators are treading a delicate line. Taiwan’s central bank has urged restraint, discouraging speculative trades through vehicles such as ETFs, and cautioning against exaggerated market commentary. It has also issued warnings to foreign investors who may be circumventing capital controls by not deploying inflows into domestic securities—a move intended to curb volatility without triggering accusations of currency manipulation from Washington.

Policy shifts and trade developments elsewhere may be compounding the pressures. Analysts observe that rapid appreciation could weaken Taiwan’s offerings amid looming U. S. tariffs and a lack of definitive agreements with Washington. Others point to structural shifts: Asian economies, Taiwan included, are unwinding dollar‑heavy positions amid growing concern over U. S. policy and economic fragility. One commentator dubbed this a “reverse Asian crisis,” pointing to a regional transfer of purchasing power back to local currencies.

Reactions continue to unfold across sectors. The logistics industry, for instance, is grappling with imbalances in shipping flows and heightened forex risk; yet it also sees potential growth through import logistics and value‑added FX‑savvy services for clients.

Altogether, Taiwan confronts a complex convergence of forces: strong export volumes feeding currency strength, speculators and hedgers accelerating the appreciation, and policy efforts seeking to stabilise markets without undermining global credibility. With export earnings vulnerable, insurers weighed down by FX losses, and the broader economy exposed to tariff dynamics, the coming months could heighten the stakes if the exchange rate remains elevated, especially in the absence of agreements that mitigate trade frictions.

Journalistic due diligence underscores that the data and figures—such as the currency’s 12 per cent gain, margin impacts for Foxconn and others, and the insurers’ USD-exposure ratios—have been corroborated across reputable sources. Reporting maintains a balanced perspective, acknowledging both the financial risks and policy responses shaping Taiwan’s export-heavy economy.

A team led by Khalil Ramadi at NYU Tandon and NYU Abu Dhabi has unveiled a swallowable, wireless capsule designed to emit light inside the gut, allowing nerve cells to be activated without surgery—a development poised to transform gastrointestinal research and therapy.

The capsule, known as ICOPS, represents a remarkable leap in non‑invasive bioengineering. It employs optogenetic technology, by which specific neurons are genetically modified to respond to light. Once the target cells become light‑sensitive, patients can ingest an LED‑equipped capsule that, when powered externally, delivers precise stimulation to regions of the gut. This allows researchers to observe and influence neuronal circuits involved in digestion with a level of control previously limited to invasive approaches.

ICOPS stands out for its battery‑free design. It receives power wirelessly via magnetic induction from an external transmitter, enabling a compact, rodent‑scale form factor suitable for testing in freely moving animals. Crafted entirely via in‑house 3D printing—micro‑LEDs and custom coils included—this capsule avoids more expensive and restrictive cleanroom fabrication techniques.

Early animal trials suggest ICOPS can target neural circuits governing critical physiological functions, offering potential new avenues for treating gut motility disorders such as gastroparesis, where the stomach fails to empty properly. Simultaneously, the ability to stimulate region‑specific neural activity may trigger metabolic and hormonal responses, hinting at applications in metabolic disease and eating disorder therapies.

ICOPS is part of a broader research portfolio pioneered by Ramadi. Earlier innovations include FLASH, an electroceutical capsule that delivers electrical stimulation to modulate hunger‑related hormones, and IMAG, which uses magnetic fields to track pill location through the gut.

Adoption of ICOPS could revolutionise how scientists study the gut’s ‘second brain’—a vast, complex neural network fundamental to bodily control but historically difficult to study in its natural state owing to the invasive nature of previous optogenetic techniques.

Materials innovation plays a central role in this advancement. By eliminating the battery and using magnetic induction, the capsule remains small and unobtrusive. Its 3D‑printed construction offers scalability, making further adaptation for varied experimental models feasible.

Looking ahead, the implications for human healthcare are significant. The precision offered by ICOPS could enable therapies targeting select neural circuits within the gut, offering fine‑tuned interventions far more sophisticated than current broad‑spectrum prokinetic or antikinetic drugs. Furthermore, the platform may evolve to provide electrical stimulation or even deliver drugs directly to targeted gut regions.

That said, the path to clinical use remains lengthy. At present, ICOPS has demonstrated efficacy in rodent models. Transition to human clinical trials may take a decade or more, as researchers must navigate regulatory approval, safety testing, and scalability concerns.

Still, the research has drawn attention across scientific and media outlets, from Gulf News dubbing it a “Light Pill” capable of unlocking gut‑brain secrets to technical summaries highlighting how light‑activated capsules are revolutionising understanding of gut‑brain interactions.

Behind the innovation is a multi‑disciplinary team including Mohammed Elsherif, Rawan Badr El‑Din, Zhansaya Makhambetova, Heba Naser, Rahul Singh, Keonghwan Oh, Revathi Sukesan, Maylis Boitet, and Sohmyung Ha, working together across divisions at NYU Abu Dhabi and NYU Tandon. The project has benefited from funding awarded by NYU Abu Dhabi and Tamkeen through the CENTMED research centre.

Rocket Lab has expanded its in‑house manufacturing strength by successfully incorporating Planetary Systems Corporation, a Maryland‑based specialist in satellite separation systems. The deal, announced on 15 November 2021 and concluded by December that year, involved $42 million in cash and 1.72 million shares of Rocket Lab stock, with an additional performance‑based stock earn‑out dependent on PSC’s performance through 2022 and 2023.

PSC, celebrated for its “Canisterized Satellite Dispenser” and Lightband separation systems, boasts a flawless 100 percent mission‑success record across more than 100 launches. Its hardware has served a broad spectrum of launch platforms—from Rocket Lab’s own Electron vehicles to those managed by SpaceX, United Launch Alliance, Northrop Grumman, and international agencies such as Arianespace, the Indian Space Research Organisation, and JAXA.

By bringing PSC into its fold, Rocket Lab enhances its vertically integrated Space Systems division, now including Photon satellite buses, Maxwell dispensers, reaction wheels, star trackers, solar solutions, flight software, and the newly added separation hardware. PSC will continue operations in Maryland under the leadership of Mike Whalen as CEO, with founder Walter Holemans remaining chief engineer.

Chunked behind this strategic move is Rocket Lab’s intent to streamline the satellite deployment value chain, offering customers a one‑stop solution—from launch services to the final separation of payloads in orbit. Founder and CEO Peter Beck noted that integrating PSC’s proven hardware “simplifies the journey to orbit” by aligning hardware, software, spacecraft, and launch into a seamless package.

Alongside the acquisition of Advanced Solutions, Inc. in October 2021, this move aligns with Rocket Lab’s broader objective to secure technology, talent, and production capacity internally, reducing external dependencies. Industry observers have characterised this as a deliberate backward integration effort. A participant in an online space‑industry discussion observed:

“It seems like they are reverse integrating into their supply chain… instead of paying for products, buy the company, make the products for yourself, and make the margin on selling to others.”

Operationally, the acquisition has borne tangible returns. In November 2022, Rocket Lab secured two contracts totalling $14 million to supply Lightband separation systems for the Space Development Agency’s Tranche 1 transport layer constellation, reinforcing its position in national security‑oriented space architecture. The Lightbands, inherited from PSC, now supply critical satellite deployments with demonstrated reliability in specialised environments.

Rocket Lab’s expanded suite of capabilities positions it advantageously within a market increasingly dominated by fully integrated space services providers. By combining its Electron launch vehicle, Photon spacecraft, separation hardware, and on‑orbit software offerings, the company provides end‑to‑end mission support—a compelling proposition for both commercial and government customers.

With growth in space demand showing no signs of abating, particularly in low-Earth orbit constellations and defence networks, consolidating key enabling technologies under one roof offers Rocket Lab both operational efficiencies and competitive edge. The PSC acquisition stands as a pivotal building block in that strategy.

A succinct pledge to resolve their border differences and reinvigorate cooperation was exchanged between Chinese President Xi Jinping and Prime Minister Narendra Modi during a summit in Tianjin. The meeting, marking Modi’s first visit to China since the border clashes of 2020, signals a strategic effort to steady bilateral ties ahead of the meeting of regional leaders.

At the outset, Modi acknowledged that disengagement along the Line of Actual Control has created a peaceful environment, underlining that tranquility along the border is essential for bilateral development. He emphasised that relations have moved in “a meaningful direction” and stressed that both countries should pursue strategic autonomy without being viewed through the lens of a third country. Xi mirrored that sentiment, contending that border issues should not define China‑India relations. He urged a focus on economic growth and expressed a hope that their meeting would “further elevate” bilateral relations to a stable trajectory.

This diplomatic retreat from escalating tensions emerges amid broader geopolitical recalibrations. The summit, bringing together more than 20 non‑Western leaders, offered a stage for Xi to advocate a new global order more favourable to the Global South, challenging Western dominance. He proposed the creation of a SCO development bank, new financial mechanisms to reduce dependence on the US dollar, AI cooperation, and a lunar research partnership.

For his part, Putin welcomed the revival of “genuine multilateralism” through the SCO framework and lauded efforts toward building alternative Eurasian security structures. The visual solidarity among the three —occasionally dubbed the “anti‑Western bloc”— underscores their shared interest in countering US influence and economic pressure, including US‑imposed tariffs on India.

India’s engagement at Tianjin reflects a broader wave of diplomatic stepping stones: direct flights have resumed, the Kailash Mansarovar Yatra has been revived, and Indian pilgrims are again welcome in Tibet. These developments follow mutual agreements on border patrolling mechanisms and a gradual easing of visa and tourism restrictions.

While the tone between Xi and Modi was markedly conciliatory, analysts caution that underlying issues persist. The legacy of the 2020 deadly Galwan clash remains a psychological and strategic fault line. Mistrust endures, and there is no immediate indication of a comprehensive border settlement or legally binding roadmap toward de‑escalation.

The SCO’s Tianjin gathering is the largest of its kind in the organisation’s history, with Xi presiding and an array of Eurasian leaders in attendance. The event signifies a collective push toward regional cooperation and institutional alternatives to Western‑led institutions.

McLaren Racing is set to be valued at in excess of £3 billion as its Middle Eastern backers move to acquire the remaining minority stake in the team. Bahrain’s Mumtalakat sovereign wealth fund and Abu Dhabi’s CYVN Holdings are preparing to buy out the 30 per cent share previously held by investors such as MSP Sports Capital, UBS O’Connor and Ares Management in a deal expected to be confirmed imminently.

This valuation marks a substantial leap from its December 2020 valuation of approximately £560 million, when MSP Sports Capital entered the picture during a fundraising round. The outcome promises significant returns for the minority investors who backed McLaren during its earlier financial challenges.

McLaren’s resurgence under chief executive Zak Brown and team principal Andrea Stella has helped propel the team back to the forefront of Formula One. Following years overshadowed by dominant rivals, McLaren clinched its first constructors’ championship in 2024, and in the current season its drivers—Oscar Piastri and Lando Norris—are locked in a fierce duel at the top of the drivers’ standings.

The sport’s expanding global appeal, driven by Liberty Media’s strategic digital outreach and the cultural phenomenon of the Netflix series Drive to Survive, has magnified team valuations across the grid. McLaren’s rise is emblematic of that broader trend.

Alongside on-track performance, McLaren has diversified into other motorsport arenas. It competes in IndyCar and has confirmed plans to enter the World Endurance Championship, notably the 24 Hours of Le Mans, beginning in 2027. Mastercard has also joined as the team’s title sponsor, in a deal slated to begin in 2026.

The Gulf investors, Mumtalakat and CYVN, currently hold control of McLaren Group Limited, the parent entity of McLaren Racing. With this deal, they will consolidate full ownership of the racing arm.

Beyond this deal, McLaren’s broader corporate structure has undergone notable change. In March 2024, Mumtalakat completed a full takeover of McLaren Group. Later, in December 2024, CYVN acquired McLaren Automotive along with a non‑controlling interest in the racing division. These moves underscore a strategic integration under Gulf ownership, spanning both competition and high-performance automotive manufacturing.

The proposed stake sale is set to be formally announced in the coming days—and might already be public by the time this report is published.

Further context: Aston Martin, another Formula One team, recently sold a minority stake in its racing operation for approximately $147 million, valuing that team at around $3.2 billion.

A colossal leap in infrastructure development is underway as OpenAI pursues the establishment of a data centre in India with a striking capacity of at least one gigawatt. The project, integral to its Stargate initiative, ushers in a new era of AI infrastructure expansion across Asia.

OpenAI is actively exploring partnerships with Indian firms to bring this gigawatt-scale facility to life, though the precise location and timeline remain unspecified. The effort aligns with its Stargate programme—an expansive, multibillion-dollar venture in collaboration with SoftBank, Oracle and MGX to develop next-generation AI infrastructure.

The planned facility stands among the largest of its kind in the region and may be formally introduced by OpenAI’s chief executive, Sam Altman, during his anticipated visit to India in September. OpenAI has already gained legal footing by registering as an entity in India and is gearing up to open its first office in New Delhi later in the year, reflecting the nation’s importance as the company’s second-largest market by user base.

Financial implications of such mega‑scale AI infrastructure are enormous. According to Jensen Huang, chief executive of Nvidia, constructing a singular gigawatt-class facility could cost around $50 billion—$35 billion directed towards Nvidia’s hardware and $15 billion for supplementary systems. OpenAI’s ambitions also include similar “AI super‑factories” in Abu Dhabi and across the United States, all under the banner of Stargate.

This enormous investment is forecast to have ripple effects across the global AI ecosystem. With Stargate estimated at up to $500 billion, it underscores OpenAI’s strategic ambition to lead in AI infrastructure and the mounting demand for AI-optimised processing capabilities. Nvidia, for example, projects AI infrastructure spending could soar to the $3‑4 trillion mark annually by 2030, bolstered by commitments like those under Stargate.

Locally, establishing such a facility in India can offer tangible advantages. A dedicated data centre promises to reduce latency for Indian users while satisfying regulatory demands for local data storage, a critical consideration for enterprise clients and government services. The endeavour complements OpenAI’s earlier move to enable local data residency for services such as ChatGPT Enterprise and its API offerings, aligning with India’s regulatory framework.

India’s data centre ecosystem is expanding rapidly. From an installed capacity of approximately 950 megawatts in 2024, projections currently estimate that figure to nearly double—approaching 2 gigawatts by 2026. However, even with such growth, the nation still accounts for just a fraction of global data centre capacity despite generating a significant portion of worldwide data streams. The arrival of a gigawatt-scale project like OpenAI’s would mark a profound increase in both capacity and technological capability.

Environmental sustainability and energy demands also emerge as critical considerations. Hyperscale data infrastructure requires vast power and cooling resources, raising pressing questions about energy sourcing, water usage, and ecological impact—matters India is progressively addressing through green data centre policies and incentives.

OpenAI’s move echoes broader trends among global tech giants expanding their Indian footprints. For instance, Reliance Industries is planning a three‑gigawatt data centre in Jamnagar; Microsoft, Amazon, and Google are investing heavily in cloud infrastructure; and India’s government continues to support initiatives through Digital India and localisation mandates.